Serum bactericidal activities and comparative pharmakokinetics of meropenem and imipenem-cilastatin

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 105-109

  Dreetz, Michaela ^a   Hamacher, Jürg ^a   Eller, Jörg ^a   Borner, Klaus ^a   Koeppe, Peter ^a   Schaberg, Tom ^a   Lode, Hartmut ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; CILASTATIN; IMIPENEM; MEROPENEM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG URINE LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ACTIVITY; VERTIGO;

EID: 0030049979     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.105     Document Type: Article

References (43)

1. Averdunk, R., and K. Borner. 1970. Korrelation der Thromboplastinzeiten bei Dicumarol-behandelten Patienten unter Verwendung verschiedener Thrombokinase-Präparate. Z. Klin. Chem Klin Biochem Dis 10:85-88.
2. Bax, R. P., W. Bastain, A. Featherstone, D. M. Wilkinson, M. Hutchinson, and S. J. Haworth. 1989 The pharmacokinetics of meropenem in volunteers. J. Antimicrob. Chemother. 24(Suppl. A):311-320.
3. Buckley, M. M., R. Brogden, L. Barradell, and K. Goa. 1992. Imipenem/ cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 44:408-444.
4. Burman, L. A., I. Nilsson-Ehle, M. Hutchinson, M. Haworth, S. J. Haworth, and S. R. Norrby. 1991. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem J. Antimicrob. Chemother. 27:219-224.
5. Calandra, G. B., F. M. Ricci, C. Wang, and K. R. Brown. 1988. The efficacy results and safety profile of imipenem/cilastatin from clinical research trials. J. Clin. Pharmacol. 28:120-127.
6. Clisshold, S. P., P. A. Tood, and D. M. Campoli-Richards. 1987. Imipenem/ cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy Drugs 33:183-241.
7. Davy, P., A. Davies, D. Livermore, D. Speller, and P. J. Daly. 1989 Meropenem (SM7338) - a new carbapenem. Antimicrob. Chemother. 24(Suppl. A):1-320.
8. Dettli, L. 1977. Elimination kinetics and dosage adjustment of drugs in patients with kidney disease. Prog Pharmacol. 17:90-96.
9. Duque, A., J. Altimiras, C. Garcia-Cases, and P. Vidal. 1991. Vertigo caused by intravenous imipenem/cilastatin. DICP Ann. Pharmacother. 25:1009.
10. Edwards, J. R., and P. J. Turner. 1992. Antibacterial activity of meropenem against 22,000 isolates tested in 41 European studies, abstr. 331, p. 250. In Abstracts of the 8th Mediterranean Congress on Chemotherapy. Mediterranean Society of Chemotherapy, Zagreb
11. Fukhara, H., N. Kusano, H. Nakamura, H. Kaneshima, Y. Irabu, K. Shimozi, K. Kitukawa, Y. Shigeno, A. Saito, T. Kakazu, et al. 1991. Clinical evaluation of imipenem/cilastatin sodium in internal medicine Jpn. J Antibiot. 44:877-885
12. Garcia-Rodriguez, J. A., J. E. Garcia-Sanchez, J. L. Munoz-Bellido, E. Garcia-Sanchez, and M. I. Garcia-Garcia. 1991. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia. J. Chemother. 3:143-146.
13. Greenblatt, D. S., and J. Koch-Weser. 1975. Clinical pharmacokinetics. N. Engl. J. Med. 193:702-705, 964-970.
14. Harabe, A., Y. Kawai, K. Kanazawa, M. Otsuki, and T. Nishino. 1992. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic. Drugs Exp. Clin. Res. 18:37-46
15. 14C-meropenem in man. Xenobiotica 11:1311-1323.
16. Huizinga, W. K. J., L. W. Baker, B. Warren, J. Chipponi, P. Valeur, J. Hoogkamp-Korstanje, and S. Karren. 1993. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections, abstr. 536, p. 217. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C
17. Kanellakopoulou, K., H. Giamarellou, P. Papdothomakos, H. Tsipras, J. Chloroyiannis, R. Theakou, and P. Sfikakis. 1993. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur. J. Clin. Microbiol. Infect Dis. 12:449-453.
18. Kayser, F. H., G. Morenzoni, A. Strassle, and K. Hadorn. 1988. Activity of meropenem against gram-positive bacteria. J. Antimicrob. Chemother. 24(Suppl A):101-112.
19. Klastersky, J., D. Didier, G. Swing, and D. Werts. 1974. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections J. Infect. Dis. 129:187-193.
20. Klotz, U. 1984. Klinische Pharmakokinetik, 2nd ed G. Fischer, Stuttgart, Germany
21. Knothe, H. 1991. Antibiotic usage for initial empirical treatment of infections in hospitalized patients in West Germany. Infection 19:127-130.
22. Koeppe, P., and C. Hamann. 1978 Zwei Methoden zur Parameterschatzung nicht linearer Regressionsfunktionen bei fehlerhaften Messdaten. EDV Med. Biol 9:112-117.
23. Koeppe, P., and C. Hamann. 1980. A program for nonlinear regression analysis to be used on desk-top computer. Comput. Prog. Biomed. 12:121-128.
24. Koeppe, P., and D. Hoeffler. 1972 Dic Verwendung cines Digitalrechners zur Entwicklung von Dosierungsempfehlunen für die Antibiotikatherapic. Arzneim.-Forsch 21:311-319
25. Loo, J. C. K., and S. Riegelman. 1970 Assessment of pharmacokinetic constants from postinfusion blood curves obtained after i.v infusion J. Pharm. Sci. 59:53-57
26. Murray, P. R., and A. C. Niles. 1990. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates. Diagn. Microbiol Inf. Dis 13:57-61.
27. Nilsson-Ehle, I., M. Hutchinson, S. J. Haworth, and S. R. Norrby. 1991. Pharmacokinetics of meropenem compared to imipenem/cilastatin in young, healthy males. Eur. J. Clin. Microbiol. Infect. Dis. 10:85-88.
28. Nord, C. E. 1993. Meropenem versus imipenem/cilastatin for treatment of intraabdominal infections, abstr 641, p. 236. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
29. Pien, F. D., and K. L. Vosti. 1974 Variation in performance of the serum bactericidal test Antimicrob. Agents Chemother. 6:330-333.
30. Reeves, D. S., and M. J. Bywater. 1976. Assay of antimicrobial agents, p. 21-78 In J. de Louvouis (ed.), Selected topics in clinical bacteriology. Balliere Tyndall, London.
31. Reller, L. B. 1986. The serum bactericidal test. Rev. Infect. Dis. 8:803-808.
32. Reller, L. B., and C. W. Stratton. 1977 Serum dilution test for bactericidal activity. II Standardization and correlation with antimicrobial assays and suceptibility tests. J. Infect Dis 136:196-204
33. Ritschel, W. A., and T. W. Robinson. 1980 Handbook of basic pharmacokinetics, 2nd ed. Drug Intelligence Publications, Inc., Washington, D.C.
34. Sartoretti, C. H. R., B. Attinger, J. Schilling, F. Largaider, and S. Geroulanos. 1992. Meropenem versus imipenem/cilastatin in the treatment of abdominal infections, abstr. 1583, p. 374. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C
35. Smith, J., A. Muzik, A. Motamedi, J. Lami, J. Hopkins, and S. Wilson. 1991. Randomized comparative study of meropenem versus imipenem/cilastatin in the treatment of skin and skin strucure infections, abstr. 612. p. 201 In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
36. Stratton, C. W., P. W. Weinstein, and L. B. Reller. 1982. Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration J Infect. Dis 145:160-168.
37. Turner, P. J., and J. R. Edwards. 1993 European multicentre comparison of in vitro activity of meropenem (MEM), imipenen (IPM), and cephalosporins, gentamicin, metromdazole and clindamycin, abstr. 720, p 190. In Program and abstracts of the 6th European Congress of Clinical Microbiology and Infectious Disease. European Society of Clinical Microbiology and Infectious Diseases, Munich.
38. Turner, P. J., and J. R. Edwards. 1993. The activity of meropenem and comparators against Pseudomonas aeruginosa strains isolated throughout Europe. In Abstracts of the 18th International Congress on Chemotherapy.
39. Vetter, N. 1992. Efficacy of meropenem in the treatment of respiratory tract infection: a comparative evaluation, abstr 232. p. 175. In Abstracts of the 8th Mediterranean Congress on Chemotherapy. Mediterranean Society of Chemotherapy, Zagreb
40. Vetter, N. 1993 Meropenem as empiric monotherapy for the treatment of hospital acquired lower respiratory tract infection, abstr 70, p 134. In Program and abstracts of the 18th International Congress on Chemotherapy, Stockholm. International Society of Chemotherapy, Oslo.
41. Wise, R., M. Logan, M. Cooper, J. P. Ashby, and J. M. Andrews. 1990 Meropenem pharmacokinetics and penetration into inflammatory exudate. Antimicrob Agents Chemother. 34:1515-1517.
42. Wolfson, J. S., and M. N. Swartz. 1985. Serum bactericidal activity as a monitor of antibiotic therapy. N. Engl. J Med. 312:968.
43. Zeneca GmbH. 1993. Laboratory manual: meropenem. Zeneca GmbH, Plankstadt, Germany.